JP2003238406A5 - - Google Patents

Download PDF

Info

Publication number
JP2003238406A5
JP2003238406A5 JP2002356114A JP2002356114A JP2003238406A5 JP 2003238406 A5 JP2003238406 A5 JP 2003238406A5 JP 2002356114 A JP2002356114 A JP 2002356114A JP 2002356114 A JP2002356114 A JP 2002356114A JP 2003238406 A5 JP2003238406 A5 JP 2003238406A5
Authority
JP
Japan
Prior art keywords
group
substituted
pharmaceutical composition
composition according
benzimidazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002356114A
Other languages
English (en)
Japanese (ja)
Other versions
JP5249484B2 (ja
JP2003238406A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2002356114A priority Critical patent/JP5249484B2/ja
Priority claimed from JP2002356114A external-priority patent/JP5249484B2/ja
Publication of JP2003238406A publication Critical patent/JP2003238406A/ja
Publication of JP2003238406A5 publication Critical patent/JP2003238406A5/ja
Application granted granted Critical
Publication of JP5249484B2 publication Critical patent/JP5249484B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002356114A 2001-12-11 2002-12-09 医薬組成物 Expired - Fee Related JP5249484B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2002356114A JP5249484B2 (ja) 2001-12-11 2002-12-09 医薬組成物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001-376954 2001-12-11
JP2001376954 2001-12-11
JP2001376954 2001-12-11
JP2002356114A JP5249484B2 (ja) 2001-12-11 2002-12-09 医薬組成物

Publications (3)

Publication Number Publication Date
JP2003238406A JP2003238406A (ja) 2003-08-27
JP2003238406A5 true JP2003238406A5 (enExample) 2006-03-30
JP5249484B2 JP5249484B2 (ja) 2013-07-31

Family

ID=27790693

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002356114A Expired - Fee Related JP5249484B2 (ja) 2001-12-11 2002-12-09 医薬組成物

Country Status (1)

Country Link
JP (1) JP5249484B2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4789180B2 (ja) * 2004-09-28 2011-10-12 第一三共株式会社 ６−置換−１−メチル−１−ｈ−ベンズイミダゾール誘導体の製造方法及びその製造中間体
CN101068770B (zh) 2004-09-28 2012-01-04 三共株式会社 制备6-取代的-1-甲基-1-h-苯并咪唑衍生物的方法及其合成中间体
EP1982718A4 (en) * 2006-02-09 2010-05-12 Daiichi Sankyo Co Ltd PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF CANCER
TW201336497A (zh) * 2007-02-08 2013-09-16 Daiichi Sankyo Co Ltd 噻唑啶二酮化合物之結晶型及其製法
US20110124692A1 (en) 2008-07-31 2011-05-26 Daiichi Sankyo Company, Limited Crystalline forms of thiazolidinedione compound and its manufacturing method
EP2311834A4 (en) * 2008-07-31 2011-11-02 Daiichi Sankyo Co Ltd CRYSTAL OF A THIAZOLIDINE CONNECTION AND METHOD FOR THE PRODUCTION THEREOF

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ282548B6 (cs) * 1992-01-22 1997-08-13 F. Hoffmann-La Roche Ag Farmaceutický přípravek
ES2129115T3 (es) * 1993-01-11 1999-06-01 Ligand Pharm Inc Compuestos que tienen actividad selectiva para los receptores de retinoides x, y medios para la modulacion de procesos mediados por receptores de retinoides x.
CA2153235C (en) * 1993-01-11 2005-08-23 Marcus F. Boehm Compounds having selectivity for retinoid x receptors
AU726450B2 (en) * 1995-10-06 2000-11-09 Ligand Pharmaceuticals Incorporated Dimer-selective RXR modulators and methods for their use
DE69726182T2 (de) * 1996-12-11 2004-08-12 Dana-Farber Cancer Institute, Inc., Boston Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor
EP0963199A1 (en) * 1996-12-31 1999-12-15 The Salk Institute For Biological Studies Treatment of disease states which result from neoplastic cell proliferation using ppar-gamma activators and compositions useful therefor
EP1019059A4 (en) * 1997-01-24 2004-01-14 Univ California USE OF FXR, PPAR-ALPHA AND LXR-ALPHA ACTIVATORS TO RESTORE THE BARRIER FUNCTION, TO PROMOTE EPIDERMIS DIFFERENTIATION, AND TO PROLIFERATE
JP3488099B2 (ja) * 1997-10-08 2004-01-19 三共株式会社 置換縮合複素環化合物
TR200202077T2 (tr) * 1999-03-11 2002-11-21 Nuclear Receptor Research Limited Prar nükleer reseptörleri için yeni ligandlar
JP4197387B2 (ja) * 1999-04-07 2008-12-17 第一三共株式会社 アミン誘導体化合物
JP4169450B2 (ja) * 1999-04-07 2008-10-22 第一三共株式会社 インスリン抵抗性改善剤
CA2369910A1 (en) * 1999-04-23 2000-11-02 Institut National De La Sante Et De La Recherche Medicale Compositions and methods for treatment of hyperproliferative diseases

Similar Documents

Publication Publication Date Title
JP2005501120A5 (enExample)
JP2010510999A5 (enExample)
JP2006507326A5 (enExample)
ZA200500253B (en) Ketones
JP2013505969A5 (enExample)
JP2006517572A5 (enExample)
WO2010070068A2 (en) Organic compounds
JP2003528872A5 (enExample)
JP2004516314A5 (enExample)
CA2529686A1 (en) 2-acylaminothiazole derivative or salt thereof
JP2014533735A (ja) 外寄生生物を防除するためのアリール誘導体の使用
RU2008136188A (ru) Противораковая фармацевтическая композиция
JP2005505583A5 (enExample)
JPH08509486A (ja) アテローム性動脈硬化症および食事障害の治療についてのチアゾリジンジオンの使用
JP2005503435A5 (enExample)
EP2632460A2 (en) Compositions and methods for treating tuberculosis
JP2005535594A5 (enExample)
JP2004521150A5 (enExample)
JP2026503618A5 (enExample)
JP2022552158A5 (enExample)
JP2009501745A5 (enExample)
JP2007505105A5 (enExample)
JP2005522492A5 (enExample)
JP2011524362A5 (enExample)
JP2003012667A (ja) キノリンカルボキサミド骨格を有する抗菌剤